1. Aggressive combined pharmacotherapy for heart failure reduces new onset atrial fibrillation
- Author
-
M Tokutome, R Matsukawa, A Noma, H Kisanuki, H Nakashima, T Watanabe, T Sakemi, K Okabe, A Okahara, S Kawai, H Matsuura, S Masuda, and S Mukai
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Backgrounds Heart failure (HF) is a risk factor for new onset atrial fibrillation (AF), and the new onset AF is associated with a worse prognosis in HF patients. It has been reported that renin-angiotensin system inhibitor (RASi), β-blocker and mineral-corticoid receptor antagonist (MRA) prevent the new onset AF in HF patients. However, the effect of combined pharmacotherapy including angiotensin receptor neprilysin inhibitor (ARNI) and sodium glucose co-transporter 2 inhibitor (SGLT2i) on AF is unknown. We investigated the impact of contemporary regimen of combined pharmacotherapy for HF (RASi/ARNI+β-blocker+MRA+SGLT2i) on new onset AF. Methods and results We retrospectively studied rEF and mrEF patients without AF admitted to our hospital due to decompensated HF between 2015 and 2021 (n=366). Long-term (The mean follow-up was 635±421 days) incidence of new onset AF was investigated with regard to medical therapies. Patients were divided into 2 groups; patients with ≤2 HF drugs (n=181) and patients with ≥3 HF drugs (n=185). Patients with ≤2 HF drugs group were older (77.3 vs 67.0 years old, P Conclusion Aggressive combined pharmacotherapy for HF may be associated with fewer new onset AF in patients with HF. Funding Acknowledgement Type of funding sources: None.
- Published
- 2022
- Full Text
- View/download PDF